No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript Summary
Biofrontera Outlines 2025 Growth Strategies With New FDA Approvals and Clinical Progress
10-K: FY2024 Annual Report
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (SBCC)